nol11 Antibody

What is NOL11 and why is it important in cellular research?

NOL11 is a nucleolar protein essential for ribosome biogenesis, specifically functioning in the human ribosomal small subunit (SSU) processome. It plays dual critical roles in both pre-rRNA processing and optimal rDNA transcription. Bioinformatic analysis has revealed that NOL11 is conserved throughout metazoans and their immediate ancestors but is not found in other phylogenetic groups . Its importance stems from its crucial role in the fundamental process of ribosome biogenesis, which requires hundreds of factors and takes place in the nucleolus. Research has shown that NOL11 interacts with hUTP4/Cirhin, and this interaction is partially disrupted by the R565W mutation that causes North American Indian childhood cirrhosis (NAIC) . Additionally, NOL11 is potentially overexpressed in certain cancer types, making it a subject of interest for cancer research .

What is the molecular structure and localization of NOL11?

NOL11 is a protein with a calculated molecular weight of approximately 81 kDa, consisting of 719 amino acids . The protein primarily localizes to the nucleus, specifically in the nucleolus . Immunofluorescence microscopy using anti-NOL11 antibodies reveals that NOL11 shows a high degree of overlap with Upstream Binding Factor (UBF), confirming its nucleolar localization . Interestingly, after treatment with Actinomycin D (ActD), a known inhibitor of Pol I transcription, NOL11 relocates to nucleolar caps and becomes enriched in pseudo-nucleolar organizing regions (pseudo-NORs) . This dynamic localization pattern provides important insights into NOL11's functional relationships with the transcription machinery.

What applications are NOL11 antibodies typically used for?

NOL11 antibodies have been validated for several key research applications:

For cytometric bead array applications, specific matched antibody pairs have been validated, such as 83391-3-PBS (capture) with 83391-2-PBS (detection) or 83391-3-PBS (capture) with 83391-1-PBS (detection) .

How can I validate the specificity of my NOL11 antibody?

Validating antibody specificity is crucial for reliable research outcomes. For NOL11 antibodies, implement these methodological approaches:

• Positive Control Samples: Use cell lines known to express NOL11, such as A-549, as well as mouse and rat testis tissues, which have been identified as positive samples .

• siRNA Knockdown Validation: Perform siRNA knockdown of NOL11 in appropriate cell lines (such as HeLa cells) and confirm reduced or absent signal in Western blot or immunofluorescence compared to control siRNA-treated cells .

• Peptide Competition Assay: Pre-incubate the antibody with the immunogen peptide (such as recombinant fusion protein containing amino acids 300-600 of human NOL11) before applying to your samples. Signal elimination indicates specificity.

• Multiple Antibody Confirmation: Compare results using antibodies from different sources or those targeting different epitopes of NOL11. Commercial options include rabbit polyclonal antibodies targeting regions like amino acids 300-600 or recombinant monoclonal antibodies .

• Mass Spectrometry Validation: For co-immunoprecipitation experiments, confirm pulled-down proteins by mass spectrometry, as demonstrated in studies identifying NOL11 as an interaction partner for hUTP4/Cirhin .

What are optimal sample preparation methods for detecting NOL11?

The detection of nucleolar proteins like NOL11 requires careful sample preparation techniques:

• Cell Lysis for Western Blot: For nuclear proteins like NOL11, standard RIPA buffer may be insufficient. Consider using nuclear extraction buffers containing higher detergent concentrations and DNase treatment to release nucleolar proteins. Sonication may be necessary to disrupt nucleolar structures.

• Fixation for Immunofluorescence: For optimal preservation of nucleolar structure, use 4% paraformaldehyde fixation for 10-15 minutes at room temperature. Avoid over-fixation which can mask epitopes.

• Permeabilization: After fixation, permeabilize cells with 0.2-0.5% Triton X-100 for 5-10 minutes to allow antibody access to nucleolar proteins.

• Antigen Retrieval for Tissue Sections: For paraffin-embedded tissues, heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is often effective for nucleolar proteins.

• Storage Considerations: Store antibodies at -80°C for long-term preservation of activity, as recommended for recombinant NOL11 antibodies .

How can I use NOL11 antibodies to study ribosome biogenesis defects?

NOL11 plays a crucial role in ribosome biogenesis, making it a valuable marker for studying defects in this process:

• Pre-rRNA Processing Analysis: Combine NOL11 immunoprecipitation with Northern blot analysis using specific oligonucleotide probes to examine pre-rRNA processing intermediates. After NOL11 knockdown, look for accumulation of the 30S pre-rRNA, indicating processing defects .

• Nucleolar Morphology Assessment: Use anti-NOL11 and anti-fibrillarin antibodies to co-stain and examine nucleolar structure. Loss of NOL11 through siRNA knockdown has been shown to result in abnormal nucleolar morphology, with cells containing only one very large nucleolus instead of the normal 1-4 nucleoli per cell .

• rDNA Transcription Assay: Implement run-on transcription assays after NOL11 knockdown to quantify the 40-50% reduction in rDNA transcription observed when NOL11 is depleted .

• ActD Challenge Studies: Treat cells with Actinomycin D and observe NOL11 relocalization to nucleolar caps and pseudo-NORs using immunofluorescence microscopy. This approach can reveal insights about NOL11's association with the transcription machinery .

• Co-immunoprecipitation with SSU Processome Components: Use antibodies against fibrillarin (like mouse monoclonal 72B9) to co-immunoprecipitate NOL11, confirming its incorporation into the SSU processome. This association is dependent on Pol I transcription and disappears after ActD treatment .

What controls are essential when studying NOL11 in cancer research?

When investigating NOL11's potential role in cancer, implement these critical controls:

• Tissue-Matched Normal Controls: Always compare cancer samples with corresponding normal tissue to accurately assess changes in NOL11 expression.

• Multiple Cancer Types Analysis: As NOL11 may be overexpressed in certain cancer types, compare across multiple cancer types to identify specific associations .

• Correlation with Proliferation Markers: Co-stain for established proliferation markers (Ki-67, PCNA) to determine whether NOL11 overexpression correlates with increased proliferation.

• Cellular Stress Response Controls: Include samples treated with nucleolar stress inducers (ActD, 5-FU) to differentiate cancer-specific changes from general stress responses.

• Technical Validation Controls: For each experiment, include:

  • Antibody specificity controls (as detailed in section 2.1)

  • Loading controls appropriate for nuclear/nucleolar proteins (e.g., lamin B1, fibrillarin)

  • For in situ hybridization of rRNA, use probes for housekeeping genes as controls

How does NOL11 function differ between normal and disease states?

Understanding NOL11's differential function requires sophisticated experimental approaches:

• Comparative Proteomics: Implement immunoprecipitation followed by mass spectrometry to identify NOL11 interaction partners in normal versus disease states. Research has shown that NOL11 interacts with hUTP4/Cirhin, and this interaction is partially disrupted by the R565W mutation associated with North American Indian childhood cirrhosis (NAIC) .

• Chromatin Immunoprecipitation (ChIP): Use NOL11 antibodies for ChIP assays to determine if NOL11 associates with specific genomic regions in normal versus disease states, particularly at rDNA loci.

• Ribosome Profiling: Compare ribosome profiles after NOL11 knockdown in normal and cancer cells to identify disease-specific alterations in translation.

• RNA-Seq Analysis: Perform RNA-seq after NOL11 depletion in different cell types to identify cell-type-specific effects on gene expression.

• Functional Recovery Experiments: In cells expressing mutant hUTP4/Cirhin (R565W), test whether overexpression of NOL11 can rescue defects in ribosome biogenesis or if additional compensatory mechanisms are required.

Why might I be getting non-specific bands in my NOL11 Western blot?

Non-specific bands are a common challenge when working with nucleolar proteins:

• Antibody Concentration: High antibody concentrations often increase background. Optimize by testing dilutions between 1:200 and 1:2000 as recommended for NOL11 Western blots .

• Protein Degradation: NOL11 may be subject to proteolytic cleavage during sample preparation. Add protease inhibitors to all buffers and maintain samples at 4°C throughout processing.

• Post-translational Modifications: NOL11 may undergo modifications altering its apparent molecular weight. Consider using phosphatase inhibitors and perform immunoprecipitation followed by mass spectrometry to identify modifications.

• Cross-reactivity: Some NOL11 antibodies may cross-react with related nucleolar proteins. Verify specificity using knockout/knockdown controls or peptide competition assays.

• Nuclear Extraction Efficiency: Incomplete nuclear extraction may result in variable NOL11 detection. Optimize nuclear extraction protocols and confirm extraction efficiency with nuclear markers.

How can I optimize NOL11 detection in immunofluorescence studies?

For clear visualization of nucleolar NOL11:

• Fixation Optimization: Test both paraformaldehyde (4%, 10-15 minutes) and methanol (-20°C, 10 minutes) fixation, as nucleolar proteins can show fixation-dependent epitope accessibility.

• Background Reduction: Block with 5-10% normal serum from the same species as the secondary antibody, supplemented with 0.1-0.3% Triton X-100.

• Antibody Validation: Confirm specificity using siRNA knockdown controls. After NOL11 knockdown, the immunofluorescence signal should be significantly reduced.

• Co-staining Strategy: Co-stain with established nucleolar markers like UBF or fibrillarin. Research has shown high overlap between NOL11 and UBF staining .

• ActD Treatment: As a functional validation, treat cells with Actinomycin D, which should cause NOL11 to relocalize to nucleolar caps and pseudo-NORs, a behavior observed in research studies .

What are the critical considerations when using NOL11 antibodies in co-immunoprecipitation?

Successful co-immunoprecipitation of nucleolar proteins requires:

• Nuclear Extract Preparation: Standard whole-cell lysates may contain insufficient nuclear proteins. Use dedicated nuclear extraction protocols with DNase treatment to release nucleolar proteins.

• Salt Concentration: Optimize salt concentration in IP buffers (typically 100-300mM NaCl) to maintain specific interactions while reducing background.

• Transcription-Dependent Interactions: Some NOL11 interactions, such as with fibrillarin, are dependent on active Pol I transcription. Research has shown this association disappears after ActD treatment .

• Crosslinking Consideration: For transient interactions, consider mild formaldehyde crosslinking (0.1-0.3%) before lysis.

• Negative Controls: Always include:

  • IgG control from the same species as the antibody

  • Lysate from NOL11 knockdown cells

  • Where applicable, samples treated with transcription inhibitors like ActD

How can NOL11 antibodies be used to explore connections between ribosome biogenesis and cancer?

The potential overexpression of NOL11 in certain cancers opens several research avenues:

• Expression Profiling: Use NOL11 antibodies in tissue microarrays across multiple cancer types to establish expression patterns and correlations with clinical outcomes.

• Functional Genomics: Combine CRISPR-Cas9 targeting of NOL11 with cancer cell phenotypic assays (proliferation, migration, invasion) to determine functional significance.

• Therapeutic Targeting Assessment: Test whether targeting NOL11 or its interaction partners sensitizes cancer cells to established ribosome biogenesis inhibitors.

• Biomarker Development: Evaluate whether NOL11 expression or localization pattern can serve as a prognostic or predictive biomarker in specific cancers.

• Ribosome Heterogeneity Analysis: Investigate whether NOL11 contributes to cancer-specific alterations in ribosome composition or function using advanced ribosome profiling techniques.

What are potential approaches for studying NOL11 in rare diseases like NAIC?

North American Indian childhood cirrhosis (NAIC) involves a mutation in hUTP4/Cirhin that partially disrupts its interaction with NOL11:

• Patient-Derived Models: Develop cell lines from NAIC patient samples or create CRISPR knock-in models of the R565W mutation to study NOL11-hUTP4/Cirhin interactions.

• Interaction Domain Mapping: Use truncated protein constructs and antibodies against specific domains to precisely map the interaction regions between NOL11 and hUTP4/Cirhin.

• Functional Rescue Experiments: Test whether overexpression of NOL11 can compensate for the R565W mutation in hUTP4/Cirhin in cellular models.

• Comparative Interactome Analysis: Use antibodies against wild-type and mutant hUTP4/Cirhin to immunoprecipitate and compare protein complexes, identifying differences in the interaction network.

• Liver-Specific Phenotypes: Investigate why the mutation causes liver-specific pathology by comparing NOL11-hUTP4/Cirhin interactions in hepatic versus non-hepatic cells.